Jumpei Kondo

Dr. Jumpei Kondo

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MSMichael L Schulte
Michael L Schulte
AFAllie Fu
Allie Fu
PZPing Zhao
Ping Zhao
JLJun Li
Jun Li
LGLing Geng
Ling Geng
HMH Charles Manning
H Charles Manning

28 March 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JKJumpei Kondo
Jumpei Kondo
HEHiroko Endo
Hiroko Endo
HOHiroaki Okuyama
Hiroaki Okuyama
OIOsamu Ishikawa
Osamu Ishikawa
HIHiroyasu Iishi
Hiroyasu Iishi
MIMasahiro Inoue
Masahiro Inoue
Primary culture of the cancer cells from patients’ tumors can provide crucial information of individual tumors, yet the technology has not been optimized until now. We developed an innovative culture method for primary colorectal cancer cells, based on the principle that cell–cell contact of cancer cells was maintained throughout the process. When tumor tissue was dissociated into cell clusters, in which cell–cell contact was retained, they rapidly formed spheroids that we termed cancer tissue-originated spheroids (CTOSs). CTOSs of colorectal cancer consisted of highly purified and viable cancer cells, and they were prepared with high efficiency. In immunodeficient mice, CTOSs formed xenograft tumors that retained the features of the parental tumors. Moreover, CTOSs were able to be cultured and expanded in vitro using a 3D culture system and stem cell culture medium. This method allowed evaluation of chemosensitivity and signal pathway activation in cancer cells from individual patients. Easy preparation and culture of pure primary cancer cells provides an innovative platform for studying cancer biology and developing personalized medicine.

17 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
JKJumpei Kondo
Jumpei Kondo
MIMasahiro Inoue
Masahiro Inoue
Drug screening—i.e., testing the effects of a number of drugs in multiple cell lines—is used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for establishing standard cancer treatment, necessitating disease models better than conventional established 2D cell lines for screening novel treatment candidates. In the present review, we outline recent progress regarding experimental cancer models having more physiological and clinical relevance for drug screening, which are important for the successful evaluation of cellular response to drugs. The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. We also review the use of cancer organoids to examine intertumor and intratumor heterogeneity, and introduce the perspective of the clinical use of cancer organoids to enable precision medicine.

21 October 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
JKJumpei Kondo
Jumpei Kondo
TETomoya Ekawa
Tomoya Ekawa
HEHiroko Endo
Hiroko Endo
KYKanami Yamazaki
Kanami Yamazaki
NTNorio Tanaka
Norio Tanaka
MIMasahiro Inoue
Masahiro Inoue
Patient‐derived cancer organoid culture is an important live material that reflects clinical heterogeneity. However, the limited amount of organoids available for each case as well as the considerable amount of time and cost to expand in vitro makes it impractical to perform high‐throughput drug screening using organoid cultures from multiple patients. Here, we report an advanced system for the high‐throughput screening of 2427 drugs using the cancer tissue‐originated spheroid (CTOS) method. In this system, we apply the CTOS method in an ex vivo platform from xenograft tumors, using machines to handle CTOSs and reagents, and testing a CTOS reference panel of multiple CTOS lines for the hit drugs. CTOS passages in xenograft tumors resulted in minimal changes of morphological and genomic status, and xenograft tumor generation efficiently expanded the number of CTOSs to evaluate multiple drugs. Our panel of colorectal cancer CTOS lines exhibited diverse sensitivities to the hit compounds, demonstrating the usefulness of this system for investigating highly heterogeneous disease.

30 August 2012 in Gut
Verified
Journal Article
Closed access
PDF file
YHYoshito Hayashi
Yoshito Hayashi
MTMasahiko Tsujii
Masahiko Tsujii
JWJun Wang
Jun Wang
JKJumpei Kondo
Jumpei Kondo
TATomofumi Akasaka
Tomofumi Akasaka
TTTetsuo Takehara
Tetsuo Takehara
Objective: MicroRNAs (miRNAs) act as tumour suppressor genes or oncogenes in the regulation of multiple carcinogenic processes. Aberrant miRNA expression is reported in Helicobacter pylori (H pylori)-related gastritis and gastric cancer. The cytotoxin-associated gene A (CagA) of H pylori has a pathophysiologically important role in gastric carcinogenesis. A study was undertaken to evaluate the effect of CagA on miRNA expression and its regulatory mechanism. Methods: The effect of CagA on miRNA expression was assessed by comprehensive miRNA microarray. The mechanisms of the in vitro and in vivo effects of CagA on histone modification and DNA methylation and the involvement of CagA-dysregulated signal transduction on let-7, an important representative miRNA in gastric carcinogenesis, were investigated. Results: In in vitro experiments, CagA significantly attenuated let-7 expression leading to Ras pathway activation. CagA enhanced c-myc, DNA methyltransferase 3B (DNMT3B) and Enhancer of Zeste homologue 2 (EZH2) expression and attenuated miR-26a and miR-101 expression, which resulted in the attenuation of let-7 expression by histone and DNA methylation. Experiments performed in CagA transgenic mice revealed that c-myc, EZH2 and DNMT3B expression were enhanced and let-7 expression was attenuated to induce Ras oncoprotein expression in the stomach, with no associated inflammation. Conclusions: H pylori CagA induces aberrant epigenetic silencing of let-7 expression, leading to Ras upregulation.

1 February 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
HEHiroko Endo
Hiroko Endo
JOJiro Okami
Jiro Okami
HOHiroaki Okuyama
Hiroaki Okuyama
TKToru Kumagai
Toru Kumagai
JUJunji Uchida
Junji Uchida
MIMasahiro Inoue
Masahiro Inoue